Abbisko Cayman Limited (HKG:2256)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
9.84
+0.08 (0.82%)
Jul 14, 2025, 4:08 PM HKT
229.10%
Market Cap 6.06B
Revenue (ttm) 536.33M
Net Income (ttm) 30.12M
Shares Out 616.22M
EPS (ttm) 0.04
PE Ratio 231.17
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,311,000
Average Volume 4,384,229
Open 9.72
Previous Close 9.76
Day's Range 9.63 - 9.92
52-Week Range 2.73 - 11.20
Beta 1.30
RSI 48.57
Earnings Date Aug 12, 2025

About Abbisko Cayman

Abbisko Cayman Limited, an investment holding company, engages in the research and development of pharmaceutical products in the People’s Republic of China. The company develops Pimicotinib, which is in Phase III clinical trial for the treatment of tenosynovial giant cell tumor; Irpagratinib for the treatment of hepatocellular carcinoma; ABSK043 that is in Phase I clinical trial for the treatment of non-small cells lung cancer; and ABSK061 for the treatment of solid tumors. It also develops Fexagratinib, which is in Phase II clinical trial for ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 281
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2256
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.